Partial liquid ventilation in adult patients with ARDS

A multicenter phase I-II trial

Ronald B. Hirschl, Steven Conrad, Roger Kaiser, Joseph B. Zwischenberger, Robert H. Bartlett, Frank Booth, Victor Cardenas

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of partial liquid ventilation (PLV) in adult patients with the acute respiratory distress syndrome (ARDS). Summary Background Data: Previous studies have evaluated gas exchange and the safety of PLV in adult patients with severe respiratory failure whose gas exchange was partially provided by extracorporeal life support (ECLS). This is the first experience with adult patients who were not on ECLS. Methods: Intratracheal perflubron in a total dose of 30.1 ± 7.1 ml/kg was administered over a period of 45 ± 9 hours to nine adult patients with mean age = 49 ± 4 years and mean PaO2/FiO2 ratio = 128 ± 7 as part of a prospective, multicenter, phase I-II noncontrolled trial. Results: Significant decreases in mean (A-a)DO2 (baseline = 430 ± 47, 48 hour = 229 ± 17, p = 0.0127 by ANOVA) and FiO2 (baseline = 0.82 ± 0.08, 48 hour = 0.54 ± 0.06, p = 0.025), along with an increase in mean SvO2 (baseline = 75 ± 3, 48 hour = 85 ± 2, p = 0.018 by ANOVA) were observed. No significant changes in pulmonary compliance or hemodynamic variables were noted. Seven of the nine patients in this study survived beyond 28 days after initiation of partial liquid ventilation whereas 5 patients survived to discharge. Three adverse events [hypoxia (2) and hyperbilirubinemia (1)] were determined to be severe in nature. Conclusions: These data suggest that PLV may be performed safely with few related severe adverse effects. Improvement in gas exchange was observed in this series of adult patients over the 48 hours after initiation of PLV.

Original languageEnglish (US)
Pages (from-to)692-700
Number of pages9
JournalAnnals of Surgery
Volume228
Issue number5
DOIs
StatePublished - Nov 1998

Fingerprint

Liquid Ventilation
Adult Respiratory Distress Syndrome
Extracorporeal Membrane Oxygenation
Gases
Analysis of Variance
Gilbert Disease
Lung Compliance
Safety
Respiratory Insufficiency
Hemodynamics

ASJC Scopus subject areas

  • Surgery

Cite this

Hirschl, R. B., Conrad, S., Kaiser, R., Zwischenberger, J. B., Bartlett, R. H., Booth, F., & Cardenas, V. (1998). Partial liquid ventilation in adult patients with ARDS: A multicenter phase I-II trial. Annals of Surgery, 228(5), 692-700. https://doi.org/10.1097/00000658-199811000-00009

Partial liquid ventilation in adult patients with ARDS : A multicenter phase I-II trial. / Hirschl, Ronald B.; Conrad, Steven; Kaiser, Roger; Zwischenberger, Joseph B.; Bartlett, Robert H.; Booth, Frank; Cardenas, Victor.

In: Annals of Surgery, Vol. 228, No. 5, 11.1998, p. 692-700.

Research output: Contribution to journalArticle

Hirschl, RB, Conrad, S, Kaiser, R, Zwischenberger, JB, Bartlett, RH, Booth, F & Cardenas, V 1998, 'Partial liquid ventilation in adult patients with ARDS: A multicenter phase I-II trial', Annals of Surgery, vol. 228, no. 5, pp. 692-700. https://doi.org/10.1097/00000658-199811000-00009
Hirschl RB, Conrad S, Kaiser R, Zwischenberger JB, Bartlett RH, Booth F et al. Partial liquid ventilation in adult patients with ARDS: A multicenter phase I-II trial. Annals of Surgery. 1998 Nov;228(5):692-700. https://doi.org/10.1097/00000658-199811000-00009
Hirschl, Ronald B. ; Conrad, Steven ; Kaiser, Roger ; Zwischenberger, Joseph B. ; Bartlett, Robert H. ; Booth, Frank ; Cardenas, Victor. / Partial liquid ventilation in adult patients with ARDS : A multicenter phase I-II trial. In: Annals of Surgery. 1998 ; Vol. 228, No. 5. pp. 692-700.
@article{050db98d4c38484687caaaeadb209968,
title = "Partial liquid ventilation in adult patients with ARDS: A multicenter phase I-II trial",
abstract = "Objective: To evaluate the safety and efficacy of partial liquid ventilation (PLV) in adult patients with the acute respiratory distress syndrome (ARDS). Summary Background Data: Previous studies have evaluated gas exchange and the safety of PLV in adult patients with severe respiratory failure whose gas exchange was partially provided by extracorporeal life support (ECLS). This is the first experience with adult patients who were not on ECLS. Methods: Intratracheal perflubron in a total dose of 30.1 ± 7.1 ml/kg was administered over a period of 45 ± 9 hours to nine adult patients with mean age = 49 ± 4 years and mean PaO2/FiO2 ratio = 128 ± 7 as part of a prospective, multicenter, phase I-II noncontrolled trial. Results: Significant decreases in mean (A-a)DO2 (baseline = 430 ± 47, 48 hour = 229 ± 17, p = 0.0127 by ANOVA) and FiO2 (baseline = 0.82 ± 0.08, 48 hour = 0.54 ± 0.06, p = 0.025), along with an increase in mean SvO2 (baseline = 75 ± 3, 48 hour = 85 ± 2, p = 0.018 by ANOVA) were observed. No significant changes in pulmonary compliance or hemodynamic variables were noted. Seven of the nine patients in this study survived beyond 28 days after initiation of partial liquid ventilation whereas 5 patients survived to discharge. Three adverse events [hypoxia (2) and hyperbilirubinemia (1)] were determined to be severe in nature. Conclusions: These data suggest that PLV may be performed safely with few related severe adverse effects. Improvement in gas exchange was observed in this series of adult patients over the 48 hours after initiation of PLV.",
author = "Hirschl, {Ronald B.} and Steven Conrad and Roger Kaiser and Zwischenberger, {Joseph B.} and Bartlett, {Robert H.} and Frank Booth and Victor Cardenas",
year = "1998",
month = "11",
doi = "10.1097/00000658-199811000-00009",
language = "English (US)",
volume = "228",
pages = "692--700",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Partial liquid ventilation in adult patients with ARDS

T2 - A multicenter phase I-II trial

AU - Hirschl, Ronald B.

AU - Conrad, Steven

AU - Kaiser, Roger

AU - Zwischenberger, Joseph B.

AU - Bartlett, Robert H.

AU - Booth, Frank

AU - Cardenas, Victor

PY - 1998/11

Y1 - 1998/11

N2 - Objective: To evaluate the safety and efficacy of partial liquid ventilation (PLV) in adult patients with the acute respiratory distress syndrome (ARDS). Summary Background Data: Previous studies have evaluated gas exchange and the safety of PLV in adult patients with severe respiratory failure whose gas exchange was partially provided by extracorporeal life support (ECLS). This is the first experience with adult patients who were not on ECLS. Methods: Intratracheal perflubron in a total dose of 30.1 ± 7.1 ml/kg was administered over a period of 45 ± 9 hours to nine adult patients with mean age = 49 ± 4 years and mean PaO2/FiO2 ratio = 128 ± 7 as part of a prospective, multicenter, phase I-II noncontrolled trial. Results: Significant decreases in mean (A-a)DO2 (baseline = 430 ± 47, 48 hour = 229 ± 17, p = 0.0127 by ANOVA) and FiO2 (baseline = 0.82 ± 0.08, 48 hour = 0.54 ± 0.06, p = 0.025), along with an increase in mean SvO2 (baseline = 75 ± 3, 48 hour = 85 ± 2, p = 0.018 by ANOVA) were observed. No significant changes in pulmonary compliance or hemodynamic variables were noted. Seven of the nine patients in this study survived beyond 28 days after initiation of partial liquid ventilation whereas 5 patients survived to discharge. Three adverse events [hypoxia (2) and hyperbilirubinemia (1)] were determined to be severe in nature. Conclusions: These data suggest that PLV may be performed safely with few related severe adverse effects. Improvement in gas exchange was observed in this series of adult patients over the 48 hours after initiation of PLV.

AB - Objective: To evaluate the safety and efficacy of partial liquid ventilation (PLV) in adult patients with the acute respiratory distress syndrome (ARDS). Summary Background Data: Previous studies have evaluated gas exchange and the safety of PLV in adult patients with severe respiratory failure whose gas exchange was partially provided by extracorporeal life support (ECLS). This is the first experience with adult patients who were not on ECLS. Methods: Intratracheal perflubron in a total dose of 30.1 ± 7.1 ml/kg was administered over a period of 45 ± 9 hours to nine adult patients with mean age = 49 ± 4 years and mean PaO2/FiO2 ratio = 128 ± 7 as part of a prospective, multicenter, phase I-II noncontrolled trial. Results: Significant decreases in mean (A-a)DO2 (baseline = 430 ± 47, 48 hour = 229 ± 17, p = 0.0127 by ANOVA) and FiO2 (baseline = 0.82 ± 0.08, 48 hour = 0.54 ± 0.06, p = 0.025), along with an increase in mean SvO2 (baseline = 75 ± 3, 48 hour = 85 ± 2, p = 0.018 by ANOVA) were observed. No significant changes in pulmonary compliance or hemodynamic variables were noted. Seven of the nine patients in this study survived beyond 28 days after initiation of partial liquid ventilation whereas 5 patients survived to discharge. Three adverse events [hypoxia (2) and hyperbilirubinemia (1)] were determined to be severe in nature. Conclusions: These data suggest that PLV may be performed safely with few related severe adverse effects. Improvement in gas exchange was observed in this series of adult patients over the 48 hours after initiation of PLV.

UR - http://www.scopus.com/inward/record.url?scp=0032470674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032470674&partnerID=8YFLogxK

U2 - 10.1097/00000658-199811000-00009

DO - 10.1097/00000658-199811000-00009

M3 - Article

VL - 228

SP - 692

EP - 700

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 5

ER -